Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Beyer

Showing results (221-230 of 225) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 225 results.
European Heart Journal|May 24, 2019
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trialStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
Research and Practice in Thrombosis and Haemostasis|August 22, 2022
Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarinIngrid M Bistervels, Roisin Bavalia, Jan Beyer-Westendorf, et al.
The European Respiratory Journal|August 30, 2020
Survival and quality of life after early discharge in low-risk pulmonary embolismStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
The Lancet. Haematology|November 9, 2019
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trialChristoph Male, Anthonie W A Lensing, Joseph S Palumbo, et al.
The New England Journal of Medicine|May 15, 2024
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral HemorrhageStuart J Connolly, Mukul Sharma, Alexander T Cohen, et al.
Pageof 23

Showing results (221-230 of 225) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 225 results.
European Heart Journal|May 24, 2019
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trialStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
Research and Practice in Thrombosis and Haemostasis|August 22, 2022
Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarinIngrid M Bistervels, Roisin Bavalia, Jan Beyer-Westendorf, et al.
The European Respiratory Journal|August 30, 2020
Survival and quality of life after early discharge in low-risk pulmonary embolismStefano Barco, Irene Schmidtmann, Walter Ageno, et al.
The Lancet. Haematology|November 9, 2019
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trialChristoph Male, Anthonie W A Lensing, Joseph S Palumbo, et al.
The New England Journal of Medicine|May 15, 2024
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral HemorrhageStuart J Connolly, Mukul Sharma, Alexander T Cohen, et al.
Pageof 23